Mark P. has over 25 years of experience in the biopharmaceutical industry, currently serving as Director of Business Development at Altasciences Preclinical Services since October 2018, focusing on drug development support from lead candidate selection to proof of concept. Concurrently, Mark P. has held the position of Director of Business Development at SNBL USA since December 2015, where responsibilities include managing client accounts and developing new business opportunities. Prior roles include Account Manager at Xenometrics, Project Manager and Sales Support at Numira Inc., and various scientific positions at organizations such as ALZA Corporation, Roche Bioscience, and Neurex Corp, where Mark P. conducted in-vivo studies, managed projects, and ensured compliance with industry regulations.
This person is not in any teams
This person is not in any offices
Shin Nippon Biomedical Laboratories Ltd
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.